Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
RedChip Companies will air interviews with Calidi Biotherapeutics (NYSE American:CLDI) and Gorilla Technology Group (Nasdaq:GRRR) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV on October 19 at 7 p.m. ET. The show reaches an estimated 73 million homes across the U.S.
Calidi Biotherapeutics is pioneering oncolytic virotherapy (OV) for cancer treatment. Their approach uses engineered viruses to target cancer cells and stimulate immune response. Calidi's cell-based technologies protect OVs from immune system elimination, potentially increasing efficacy.
Gorilla Technology, with 22 years of experience and 29 global patents, specializes in digital transformation solutions. Their technologies include edge AI, big data analytics, and IoT security, serving sectors like government and manufacturing. Gorilla has buy ratings from three analysts with a mean price target of $29.50.
RedChip Companies trasmetterà interviste con Calidi Biotherapeutics (NYSE American:CLDI) e Gorilla Technology Group (Nasdaq:GRRR) nel programma RedChip Small Stocks, Big Money™ su Bloomberg TV il 19 ottobre alle 19:00 ET. Il programma raggiunge circa 73 milioni di case negli Stati Uniti.
Calidi Biotherapeutics è all'avanguardia nella viroterapia oncolitica (OV) per il trattamento del cancro. Il loro approccio utilizza virus ingegnerizzati per colpire le cellule tumorali e stimolare la risposta immunitaria. Le tecnologie cellulari di Calidi proteggono gli OV dall'eliminazione da parte del sistema immunitario, aumentando potenzialmente l'efficacia.
Gorilla Technology, con 22 anni di esperienza e 29 brevetti globali, è specializzata in soluzioni di trasformazione digitale. Le loro tecnologie includono AI edge, analisi dei big data e sicurezza IoT, servendo settori come il governo e la manifattura. Gorilla ha raccomandazioni di acquisto da parte di tre analisti con un prezzo obiettivo medio di $29,50.
RedChip Companies transmitirá entrevistas con Calidi Biotherapeutics (NYSE American:CLDI) y Gorilla Technology Group (Nasdaq:GRRR) en el programa RedChip Small Stocks, Big Money™ en Bloomberg TV el 19 de octubre a las 7 p.m. ET. El programa llega a aproximadamente 73 millones de hogares en los EE. UU.
Calidi Biotherapeutics está a la vanguardia de la viroterapia oncolítica (OV) para el tratamiento del cáncer. Su enfoque utiliza virus diseñados para atacar las células cancerosas y estimular la respuesta inmunológica. Las tecnologías basadas en células de Calidi protegen a los OV de la eliminación por parte del sistema inmunológico, aumentando potencialmente la eficacia.
Gorilla Technology, con 22 años de experiencia y 29 patentes globales, se especializa en soluciones de transformación digital. Sus tecnologías incluyen AI en el borde, análisis de big data y seguridad IoT, atendiendo sectores como el gobierno y la manufactura. Gorilla tiene calificaciones de compra de tres analistas con un objetivo de precio medio de $29.50.
레드칩 컴퍼니즈는 칼리디 바이오테라퓨틱스 (NYSE American:CLDI)와 고릴라 테크놀로지 그룹 (Nasdaq:GRRR)와의 인터뷰를 10월 19일 오후 7시에 블룸버그 TV의 레드칩 스몰 스톡스, 빅 머니™ 프로그램에서 방송할 예정입니다. 이 프로그램은 미국 전역에 약 7300만 가구에 도달합니다.
칼리디 바이오테라퓨틱스는 암 치료를 위한 온콜리틱 바이로테라피(OV)를 선도하고 있습니다. 그들의 접근법은 엔지니어링된 바이러스를 사용하여 암세포를 표적하고 면역 반응을 자극합니다. 칼리디의 세포 기반 기술은 OV를 면역 시스템의 제거로부터 보호하여 잠재적으로 효능을 증가시킵니다.
고릴라 테크놀로지는 22년의 경험과 29개의 글로벌 특허를 가지고 있으며 디지털 전환 솔루션을 전문으로 합니다. 그들의 기술에는 엣지 AI, 빅데이터 분석, IoT 보안이 포함되며, 정부 및 제조와 같은 분야에 서비스를 제공합니다. 고릴라는 세 명의 애널리스트로부터 구매 등급을 받았으며 평균 가격 목표는 $29.50입니다.
RedChip Companies diffusent des interviews avec Calidi Biotherapeutics (NYSE American:CLDI) et Gorilla Technology Group (Nasdaq:GRRR) dans l'émission RedChip Small Stocks, Big Money™ sur Bloomberg TV le 19 octobre à 19h00 ET. L'émission atteint environ 73 millions de foyers à travers les États-Unis.
Calidi Biotherapeutics est à la pointe de la virothérapie oncolytique (OV) pour le traitement du cancer. Leur approche utilise des virus conçus pour cibler les cellules cancéreuses et stimuler la réponse immunitaire. Les technologies cellulaires de Calidi protègent les OV de l'élimination par le système immunitaire, augmentant potentiellement l'efficacité.
Gorilla Technology, avec 22 ans d'expérience et 29 brevets mondiaux, se spécialise dans les solutions de transformation numérique. Leurs technologies incluent l'IA en périphérie, l'analyse de big data et la sécurité IoT, servant des secteurs tels que le gouvernement et la fabrication. Gorilla a des recommandations d'achat de la part de trois analystes avec un objectif de prix moyen de 29,50 $.
RedChip Companies wird Interviews mit Calidi Biotherapeutics (NYSE American:CLDI) und Gorilla Technology Group (Nasdaq:GRRR) in der Sendung RedChip Small Stocks, Big Money™ auf Bloomberg TV am 19. Oktober um 19 Uhr ET ausstrahlen. Die Sendung erreicht schätzungsweise 73 Millionen Haushalte in den USA.
Calidi Biotherapeutics ist Pionier in der onkolytischen Virotherapie (OV) zur Krebsbehandlung. Ihr Ansatz nutzt entwickelte Viren, um Krebszellen anzugreifen und die Immunantwort zu stimulieren. Calidis zellbasierte Technologien schützen OVs vor der Eliminierung durch das Immunsystem, was potenziell die Wirksamkeit erhöht.
Gorilla Technology, mit 22 Jahren Erfahrung und 29 globalen Patenten, ist auf digitale Transformationslösungen spezialisiert. Ihre Technologien umfassen Edge AI, Big Data-Analytik und IoT-Sicherheit und bedienen Sektoren wie die Regierung und die Fertigung. Gorilla hat Kaufempfehlungen von drei Analysten mit einem durchschnittlichen Kursziel von 29,50 $ erhalten.
- Gorilla Technology has buy ratings from three analysts with a mean price target of $29.50
- Gorilla Technology holds 29 granted patents globally
- Calidi Biotherapeutics is developing promising oncolytic virotherapy for cancer treatment
- Calidi's cell-based technologies show potential for higher efficacy in cancer treatment
- None.
ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Gorilla Technology Group Inc. (Nasdaq:GRRR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
Gorilla Technology: https://www.redchip.com/assets/access/grrr_access
In an exclusive interview, Stephen Thesing, Chief Business Officer of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Calidi is at the forefront of oncolytic virotherapy (OV), a promising multi-billion-dollar area in cancer treatment. Calidi is pioneering the development of both systemic and localized OVs, leveraging engineered viruses to target and destroy cancer cells while arming the immune system for a comprehensive attack on tumors. Calidi's cell-based technologies uniquely protect OVs from immune system elimination, ensuring higher efficacy and opening the tumor microenvironment to treatment. This approach has shown promising efficacy in initial studies, while their breakthrough IV-based technology and direct tumor administration methods differentiate them within the multi-billion-dollar oncology field.
Jay Chandan, Chairman and CEO of Gorilla Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. With over 22 years of operational excellence and a portfolio of 29 granted patents globally, Gorilla has established itself as a leader in delivering transformative solutions that drive large-scale digital transformation. The company's advanced technologies, including edge AI, big data analytics, IoT security, and virtualization infrastructure, empower clients across critical sectors such as government, public safety, manufacturing, and energy management to create smarter, safer and more efficient environments. Gorilla's strong financial foundation, innovative technology, and strategic market expansion provide a solid basis for long-term value creation as it continues to lead in the global digital transformation landscape. Gorilla has buy ratings and a mean price target of
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
About Gorilla Technology Group Inc.
Headquartered in London U.K., Gorilla is a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. We provide a wide range of solutions, including, Smart City, Network, Video, Security Convergence and IoT, across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education, by using AI and Deep Learning Technologies.
Our expertise lies in revolutionizing urban operations, bolstering security and enhancing resilience. We deliver pioneering products that harness the power of AI in intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics and advanced cybersecurity technologies. By integrating these AI-driven technologies, we empower Smart Cities to enhance efficiency, safety and cybersecurity measures, ultimately improving the quality of life for residents.
For more information, please visit our website: https://www.gorilla-technology.com/
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
--END--
SOURCE: RedChip
View the original press release on accesswire.com
FAQ
When will the interviews with Calidi Biotherapeutics (CLDI) and Gorilla Technology (GRRR) air on Bloomberg TV?
What is Calidi Biotherapeutics' (CLDI) main focus in cancer treatment?
What is the current analyst consensus on Gorilla Technology Group (GRRR) stock?
What are the main technologies offered by Gorilla Technology Group (GRRR)?
